Study of IbrutNCT03112174inib Combined With Venetoclax in Subjects With Mantle Cell Lymphoma (SYMPATICO)

Official Title

Phase 3 Study of Ibrutinib in Combination With Venetoclax in Subjects With Mantle Cell Lymphoma


This Phase 3 multinational, randomized, double-blind study is designed to compare the efficacy and safety of the combination of ibrutinib and venetoclax vs. ibrutinib and placebo in subjects with MCL.

Trial Description

Primary Outcome:

  • Occurrence of Tumour Lysis Syndrome (TLS) (Safety Run-in Period)
  • Occurrence of Dose Limiting Toxicities (DLT) (Safety Run-in Period)
  • Percentage of participants experiencing Adverse Events (Safety Run-in Period)
  • Overall response rate (ORR) (Safety Run-in Period)
  • Duration of Response (DOR) (Safety Run-in Period)
  • Progression-free Survival (PFS) (Safety Run-in Period)
  • Overall Survival (OS) (Safety Run-in Period)
  • Progression-free Survival (PFS) (Randomization Period)
  • Complete Response (CR) (Treatment-Naive Arm)
Secondary Outcome:
  • Complete Response (CR) (Randomization Period)
  • Overall response rate (ORR) (Randomization Period and Treatment-Naive Arm)
  • MRD-negative remission rate in participants who achieve CR per investigator assessment (Randomization Period and Treatment-Naive Arm)
  • Overall Survival (OS) (Randomization Period and Treatment-Naive Arm)
  • Duration of Response (DOR) (Randomization Period and Treatment-Naive Arm)
  • Time to Next Treatment (TTNT) (Randomization Period and Treatment-Naive Arm)
  • Percentage of participants experiencing Adverse Events (Randomization Period)
  • Occurrence of Tumour Lysis Syndrome (TLS) (Randomization Period)
  • Cmax if Ibrutinib (Randomization Period)
  • Tmax if Ibrutinib (Randomization Period)
  • AUClast if Ibrutinib (Randomization Period)
  • Half-Life (T1/2) if Ibrutinib (Randomization Period)
  • Cmax of Venetoclax (Randomization Period)
  • Tmax of Venetoclax (Randomization Period)
  • AUC of Venetoclax (Randomization Period)
  • Time to worsening in FACT-Lym subscale of the health-related quality of life (Randomization Period) questionnaire (FACT-Lym)
  • Duration of CR (Treatment-Naive Arm Period)
  • Progression-free Survival (PFS) (Treatment-Naive Arm Period)

View this trial on

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.


Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society